(Q39882228)

15 September 2017

Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs (English)

1 reference

15 September 2017

0 references

anti-retroviral agent

0 references

author name string

D J B Marks

1

1 reference

15 September 2017

K Dheda

2

1 reference

15 September 2017

R Dawson

3

1 reference

15 September 2017

G Ainslie

4

1 reference

15 September 2017

R F Miller

5

1 reference

15 September 2017

language of work or name

1 reference

1 May 2009

1 reference

International Journal of STD & AIDS

15 September 2017

1 reference

15 September 2017

20

1 reference

15 September 2017

5

1 reference

15 September 2017

339-345

1 reference

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

15 September 2017

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Diagnostic accuracy of an integrated respiratory guideline in identifying patients with respiratory symptoms requiring screening for pulmonary tuberculosis: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

International standards for tuberculosis care

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Tuberculosis in HIV-infected patients: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Transmission of tuberculosis in a high incidence urban community in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

An official ATS statement: hepatotoxicity of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Pyridoxine supplementation during isoniazid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Peripheral CD4 loss of regulatory T cells is associated with persistent viraemia in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2008.008361

21 January 2018

Identifiers

DOI

10.1258/IJSA.2008.008361

1 reference

15 September 2017

1 reference